BioBuzz: NanoViricides Inc. (NYSE: NNVC), Hepion Pharmaceuticals Inc. (NASDAQ: HEPA), Gilead Sciences (NASDAQ: GILD) and American Premium Water Corp. (OTC:HIPH)

0
570

The potential to profit from revolutionary new treatments makes biotech one of the hottest industries for investors to target.

Biotech stocks have delivered sizzling overall returns over the last few years. New drugs have improved the lives of patients and made big profits for investors in the process. The future looks promising for biotech stocks as a group as well. Several currently successful drugs have room to increase sales.

NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus

NanoViricides, Inc. (NYSE: NNVC) a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is confirming public disclosures in articles by various industry journals and other articles, that it is working on developing a treatment for the novel coronavirus 2019-nCoV, or the Wuhan coronavirus.

“We have already initiated a program for developing a treatment for the 2019-nCOV,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, “Our platform technology enables possibly the most rapid pathway for new drug development against viral diseases. Of course, we will need support from governmental and international agencies such as the US CDC, WHO, and Chinese CDC to successfully develop these treatments, and, if developed, to get them to the patients in the fastest possible time. At this time, the Company does not have a collaboration with any of these agencies, and we have not been contacted by any of these entities or asked to develop a treatment for this virus. We had collaborations with the CDC and USAMRIID in the past. The Company intends to pursue a relevant collaboration for testing of our drug candidates soon.”

American Premium Water Corp Announces Expanded Vanexxe Product Distribution in Australia

American Premium Water Corporation (OTC: HIPH) announced yesterday that Canyon Create Corp, the manufacturer of Vanexxe, has entered into a Letter of Intent (LOI) with Nutra Pty. Ltd. (Nutra), an Australian corporation with extensive reach in distribution of personal products, to engage in the licensed production and sale of Vanexxe throughout Australia and Southeast Asia. The Company has an equitable interest in Canyon Create Corp.

American Premium Water Corporation CEO Ryan Fishoff commented, “This is an exciting day for Vanexxe! Not only is this ground breaking product expanding to Australia, its also being evaluated by the TGA to be classified for therapeutic use. If approval is given, it will greatly expand the number of channels that can sell the product. It will also offer further validation of the product and its efficacy. The LOI with Nutra Pty falls in line with our focus on international expansion, and has been in the works for some time, as the Company stated back in July that it was in discussions with distributors across the Pacific Rim. Establishing a foothold in the Pacific has been a stated goal of the Company’s. As we move into 2020, we will continue to focus on expanding into this region. I look forward to updating shareholders when the Nutra Pty LOI is completed and the Company’s other activities in the area.”

Hepion Pharmaceutical’s NASH Drug Candidate Shows Superior Antifibrotic Efficacy in Expanded Human Liver Study

Last week, Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) announced positive findings from an expanded study with human precision cut liver slices (“PCLS”). In this specialized experimental model using human liver tissue, Hepion’s drug candidate, CRV431, prevented experimentally induced liver fibrosis to a greater extent than four other leading NASH drug candidates: obeticholic acid (“OCA”, an FXR agonist), elafibranor (a PPARα/δ agonist), resmetirom (a THR-β agonist), and Aramchol (an SCD1 inhibitor). These results support the potential for CRV431 to exert potent antifibrotic activity in NASH.

Gilead Tests Potential Ebola Treatment Nuc inhibitor GS-5734 for treating Coronavirus Infection

Gilead Sciences (NASDAQ: GILD) announced that it is currently in the process of evaluating the use of its experimental Ebola candidate, Nuc inhibitor GS-5734, for treating 2019-nCov infection. The company is currently engaged in active discussions with clinicians and researchers in China and the United States.

The US National Institute of Allergy and Infectious Diseases (NIAID) stated that it is in discussions with Gilead about the use of Remdesivir as a potential treatment for coronavirus. However, it should be noted that Gilead is not the only pharma company working in that direction.

Remdesivir was originally developed for treating Ebola patients but was found to be ineffective. Coronavirus mainly attacks the respiratory system and may lead to conditions such as Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome (MERS). Gilead has claimed that the medication has been found to be active against other coronaviruses in animal and lab studies.

LEAVE A REPLY

Please enter your comment!
Please enter your name here